Literature DB >> 10869288

Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent.

E Siewert1, R Bort, R Kluge, P C Heinrich, J Castell, R Jover.   

Abstract

Expression of cytochromes P450 (CYP) is markedly reduced during inflammatory processes. In vitro studies with hepatocytes have shown that cytokines generated during these processes down-regulate CYP. However, it is not clear to what extent each individual cytokine contributes to the overall reduced expression of the various CYP isoenzymes in vivo. Interleukin 6 (IL-6), a major player during inflammatory processes, is recognized as the most important cytokine modulating the hepatic expression of acute-phase protein (APP) genes. For this reason, we selected the IL-6(-/-) mouse as a model to investigate the role of IL-6 in the down-regulation of hepatic CYP during experimental inflammation. Our results show that the reduction in messenger RNA (mRNA) levels of CYP1A2, CYP2A5, and CYP3A11 during turpentine-induced inflammation was abrogated in IL-6-deficient mice, confirming that IL-6 is an indispensable player for the down-regulation of hepatic CYP during aseptic inflammation. Moreover, the different CYP isoenzymes showed a variable grade of dependence on IL-6, CYP2A5 being the most sensitive one. In the case of CYP2E1, differences between IL-6(-/-) and wild-type mice were no longer maintained after 24 hours, suggesting a delayed, rather than abrogated, CYP down-regulation in the absence of IL-6. As opposed to that, hepatic CYP repression took place in IL-6-deficient mice during lipopolysaccharide (LPS)-mediated inflammation. This contrasting behavior observed for CYP is surprisingly similar to the one seen for extracellular (serum amyloid A, beta-fibrinogen) and intracellular (metallothionein-1) APPs and points to the fact that, in the model of bacterial inflammation (LPS), the effects of IL-6 on CYP down-regulation are likely to be substituted by other cytokines or mediators.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869288     DOI: 10.1053/jhep.2000.8532

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

Review 1.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

2.  Acute and chronic effects of IL-22 on acetaminophen-induced liver injury.

Authors:  Dechun Feng; Yan Wang; Hua Wang; Honglei Weng; Xiaoni Kong; Brittany V Martin-Murphy; Yongmei Li; Ogyi Park; Steven Dooley; Cynthia Ju; Bin Gao
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

Review 3.  Regulation of drug-metabolizing enzymes by local and systemic liver injuries.

Authors:  Yan Guo; Bingfang Hu; Yang Xie; Timothy R Billiar; Jason L Sperry; Min Huang; Wen Xie
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-01-28       Impact factor: 4.481

4.  Exposure of precision-cut rat liver slices to ethanol accelerates fibrogenesis.

Authors:  Courtney S Schaffert; Michael J Duryee; Robert G Bennett; Amy L DeVeney; Dean J Tuma; Peter Olinga; Karen C Easterling; Geoffrey M Thiele; Lynell W Klassen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-01       Impact factor: 4.052

5.  Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen.

Authors:  Ryan D Kinloch; Choon-Myung Lee; Nico van Rooijen; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2011-05-06       Impact factor: 5.858

6.  Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats.

Authors:  V G N V Prasad; Ch Vivek; P Anand Kumar; P Ravi Kumar; G S Rao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-20       Impact factor: 2.441

7.  Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease.

Authors:  Edward T Morgan; Cene Skubic; Choon-Myung Lee; Kaja Blagotinšek Cokan; Damjana Rozman
Journal:  Drug Metab Rev       Date:  2020-09-08       Impact factor: 4.518

8.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

9.  The effects of intestinal LPS exposure on inflammatory responses in a porcine enterohepatic co-culture system.

Authors:  Erzsebet Paszti-Gere; Gabor Matis; Orsolya Farkas; Anna Kulcsar; Orsolya Palocz; Gyorgy Csiko; Zsuzsanna Neogrady; Peter Galfi
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

Review 10.  Tocilizumab in pediatric rheumatology: the clinical experience.

Authors:  Reut Gurion; Nora G Singer
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.